Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medigene Immunotherapies GmbH currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, indicating that the company's current filings are being reviewed by multiple individuals. Despite having two examiners, the portfolio is concentrated within 1 distinct art unit. This suggests that the company's innovations, while requiring multiple reviews, fall under a specific technical classification within the biotechnology sector. This concentration allows for a consistent technical strategy across the active matters.
The busiest examiner for Medigene Immunotherapies GmbH is BUNNER, BRIDGET E, who is managing 1 busiest examiner pending action. With 2 pending office actions and 2 distinct examiners, the workload is divided, with each examiner handling one matter. This structure provides the company with diverse perspectives from 2 distinct examiners while maintaining a consistent technical focus within 1 distinct art unit. Practitioners must tailor their responses to the specific styles of both examiners while adhering to the standards of the single art unit involved. The use of 2 distinct examiners reduces the risk of a single subjective interpretation.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.5% | +19.9% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | BUTTICE, AUDREY L | 97d overdue |
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | BUNNER, BRIDGET E | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §112 | Final Rejection | 97d overdue | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial